五合一脑膜炎球菌疫苗（Penmenvy）获 FDA 批准可帮助预防 MenABCWY
葛兰素史克公司 (LSE/NYSE: GSK) 宣布，美国食品药品监督管理局 (FDA) 已批准 PENMENVY（脑膜炎球菌 A、B、C、W 和 Y 组疫苗）供 10 至 25 岁人群使用。该疫苗针对通常导致侵袭性脑膜炎球菌病 (IMD) ...
GSK任命新独立非执行董事，牛津大学医学专家将加入董事会
市值740亿美元的全球制药巨头GSK plc（LSE/NYSE: GSK）今日宣布，将任命牛津大学医学科学部主任Gavin Screaton博士为公司独立非执行董事，任期自2025年5月1日起生效。Screaton博士将接替服务九年后退休的Jesse ...
腾讯网8 天
FDA批准GSK潜在重磅疫苗！
▎药明康德内容团队编辑GSK日前宣布，美国FDA已批准其组合疫苗Penmenvy（MenABCWY）上市，在10~25岁人群中使用。这款疫苗针对脑膜炎球菌中最常见的5大血清群，它们通常是导致侵袭性脑膜炎球菌病（IMD）的原因。此前，该疗法入选了业内知 ...
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory ...
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
pharmaphorum6 天
GSK gets ready for its next big vaccine launch
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
重磅疫苗获批！你了解脑膜炎球菌病的威胁吗？
你知道脑膜炎球菌病的潜在威胁吗？这一罕见却严重的疾病每年导致数以万计的感染病例，尤其在10至25岁的人群中，感染风险更高。最近，GSK宣布其组合疫苗Penmenvy（MenABCWY）获得美国FDA批准，这无疑是在防控脑膜炎球菌病道路上的一次重要突破。
来自MSN6 天
GSK’s Penmenvy meningococcal vaccine gains FDA approval
The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
The Pharma Letter6 天
GSK’s Penmenvy wins FDA approval
UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...
GSK新冠肺阻塞治疗药物Nucala在中国获审查受理
市值730亿美元、毛利率高达72%的制药巨头GSK plc（LSE/NYSE: GSK）今日宣布，中国国家药品监督管理局已受理Nucala（mepolizumab）用于嗜酸性表型慢性阻塞性肺疾病（COPD）附加治疗的新药申请。
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
GSK reports FDA approves Penmenvy 5-in-1 meningococcal vaccine
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against ...
Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...